Progress in Blood Glucose Monitoring in Patients with Hepatogenic Diabetes

作者全名："Cai, Gu-Hao; Yuwen, Tian-Yi; Wang, Tian-Pu; Shi, Xiang"

作者地址："[Cai, Gu-Hao; Wang, Tian-Pu] Jiangsu Univ, Sch Med, Zhenjiang 212013, Jiangsu, Peoples R China; [Yuwen, Tian-Yi] Chongqing Med Univ, Clin Coll 1, Chongqing 401331, Peoples R China; [Shi, Xiang] Nanjing Med Univ, Sch Clin Med 1, Nanjing 211166, Jiangsu, Peoples R China"

通信作者："Shi, X (通讯作者)，Nanjing Med Univ, Sch Clin Med 1, Nanjing 211166, Jiangsu, Peoples R China."

来源：JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS

ESI学科分类：BIOLOGY & BIOCHEMISTRY

WOS号：WOS:000996153000001

JCR分区：Q4

影响因子：0.8

年份：2023

卷号：37

期号：4

开始页：1745

结束页：1752

文献类型：Review

关键词：blood glucose monitoring; cirrhosis; hepatogenic diabetes (HD); insulin

摘要："Hepatogenic diabetes (HD) is secondary to chronic liver parenchymal damage. The main manifestations of HD are hyperglycemia and impaired glucose tolerance, which is caused due to the destruction of the islet cells of pancreas, resulting in the disruption of glucose metabolism. Liver disease and diabetes mellitus are closely related and influence each other. Liver disease may lead to a rise in blood glucose and hence diabetes, which further affects the recovery and treatment of liver disease. It also promotes the deterioration of the liver to a certain extent, because the relationship between cirrhosis and diabetes is highly significant. However, in clinical practice, it is easy for medical personnel to ignore blood glucose in patients with early liver disease, possibly missing the early diagnosis of HD. Therefore, it is important to monitor the blood glucose in patients with liver disease. In this study, we discuss several mainstream blood glucose monitoring techniques to facilitate further research especially in HD."

基金机构：　

基金资助正文：